Novo Nordisk’s once‐weekly injectable, Ozempic (semaglutide), originally developed for type 2 diabetes, has increasingly attracted attention in Egypt, not just for its blood-sugar-lowering benefit ...

Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

The results showed that semaglutide improved both short-term and long-term memory in the Alzheimer’s model mice. In a test ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic ...

Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a ...

Ozempic (semaglutide) is a brand-name prescription drug used to manage type 2 diabetes and lower the risk of kidney and heart complications in people with both diabetes and chronic kidney disease.

Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...